# 2025-18110: DEA Boosts Amphetamine Quotas: More Meds for 2025 Without Overproduction

2025-18110, Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2025 Pursuant to 21 U.S.C. 826(h), is a Federal Register notice from Justice Department, Drug Enforcement Administration published 2025-09-19, effective 2025-09-19 (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2025-18110
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-18110
- Title: Adjustment to the Aggregate Production Quota for Lisdexamfetamine and d-Amphetamine (for Conversion) for 2025 Pursuant to 21 U.S.C. 826(h)
- Type: Notice
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 45249
- Published: 2025-09-19
- Effective: 2025-09-19
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

DEA Boosts Amphetamine Quotas: More Meds for 2025 Without Overproduction

## Summary

The DEA is changing how much lisdexamfetamine and d-amphetamine can be made in 2025. This affects drug makers who need to follow new production limits to meet demand safely and legally. The update is happening quickly to stick to important deadlines, but it doesn’t involve any new costs for the public.

## Abstract

The Drug Enforcement Administration (DEA) is adjusting the 2025 aggregate production quota for the schedule II controlled substances lisdexamfetamine and d-amphetamine (for conversion). In making this determination, DEA has considered the factors set forth in 21 CFR 1303.13(b) in accordance with 21 U.S.C. 826(a) and is expediting publication of this determination to comply with the timeframes specified in 21 U.S.C. 826(h)(1).

## Effects PRIA read

- 2025 Production Limits for Two Stimulants: mixed, medium. The DEA adjusted the 2025 aggregate production quota for the Schedule II substances lisdexamfetamine and d-amphetamine (for conversion). Drug manufacturers must follow the new 2025 production limits and the DEA expedited publication to meet the timeframes in 21 U.S.C. 826(h)(1).
- No New Public Costs Announced: benefit, low. The DEA stated this adjustment does not involve any new costs for the public. The change is an administrative adjustment to 2025 production quotas and was published quickly to meet statutory timeframes.

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-18110 on federalregister.gov](https://www.federalregister.gov/documents/2025/09/19/2025-18110/adjustment-to-the-aggregate-production-quota-for-lisdexamfetamine-and-d-amphetamine-for-conversion)
- [2025-18110 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-09-19/pdf/2025-18110.pdf)

## Related
- [Previous: 2025-18109, Silicon Metal From Russia; Scheduling of an Expedited Five-Year Review](https://policyrisk.com/federal-register/2025-18109)
- [Next: 2025-18112, Agency Information Collection Activities; Comment Request; AmeriCorps State and…](https://policyrisk.com/federal-register/2025-18112)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-18110 (as of 2026-06-08).
